PCV28 Clinical impact of treatment persistence in patients with atrial fibrillation  by Evers, T. & Diamantopoulos, A.
A276 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
research (CER) in Washington State’s Learning Healthcare System - the 
Comparative Effectiveness Research Translation Network (CERTAIN). METHODS: 
Leveraging the infrastructure of the Surgical Care and Outcomes Assessment 
Program (SCOAP), a statewide coordinated quality improvement program that 
tracks surgical outcomes in hospitals, we created an infrastructure for 
conducting CER/PCOR. We are using the CERTAIN network to conduct a 
pragmatic clinical trial – a multi-site, prospective, observational cohort study of 
patients in community settings with peripheral artery disease (PAD) treated with 
open surgical, endovascular, or conservatively managed care. Clinical and 
patient-reported outcomes (PRO) are collected at baseline, 30-days, 6- and 12-
months post intervention. The primary outcome is the change in scores on the 
Walking Impairment Questionnaire. The SCOAP Medical Director engaged PAD-
treating vascular surgeons, interventional radiologists and cardiologists. Study 
staff educated all institutional review boards about pragmatic trials. The SCOAP 
CERTAIN Survey Center administers all PRO surveys using a mode of 
administration of each patient’s choice (e.g. web-based, paper-pencil); and 
deploys vigorous follow-up contact algorithms to retain patients. RESULTS: Over 
18-months, 15 sites have been engaged and are enrolling patients. Over 5500 
medical records have been screened; 1016 patients (18%) with PAD identified. 
415/1,016 (41%) met all inclusion criteria and received enrollment packets, 193 
are actively participating, 14 have completed the study. Enrollment continues 
through September 2013. In companion work, CERTAIN Investigators developed 
their own ‘symptom’ instrument, informed by interviews with 11 patients; and 
are conducting a sub-study to compare scores on PRO instruments administered 
using various modes of administration. CONCLUSIONS: This CERTAIN PAD study 
illustrates the effort required to conduct a pragmatic trial. As the nation 
embraces the research paradigm of CER, Washington State’s Learning Healthcare 
System is modeling success.  
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OBJECTIVES: Heart failure (HF) is associated with increased risk of dementia and 
dementia is an independent predictor of hospitalization in HF patients. Studies 
show dyslipidemia may be involved in the pathogenesis of dementia. However, it 
is unclear whether statins are associated with risk of dementia in HF patients. 
The present study examines the effectiveness of statins to prevent dementia in 
HF patients. METHODS: This retrospective, longitudinal study used a cohort of 
patients with HF identified from a local Medicare advantage prescription drug 
plan to examine incidence of dementia with up to 3 years of follow up period. 
Multivariable time dependent Cox model and inverse-probability-of-treatment 
weighting (IPTW) of marginal structural model were used to estimate the risk of 
developing dementia controlling for sociodemographic factors, comorbidities, 
comedications, appropriate laboratory measures, and potential time-varying 
confounding affected by previous treatment (hospitalization and low density 
lipoprotein test). Adjusted dementia rate ratios were estimated among current 
and former statin users, as compared with nonusers. RESULTS: The study 
included a total of 8062 HF patients (mean age 74.47±9.21 years) of which 1135 
(14.08 %) patients were diagnosed with dementia during the median follow up of 
22 months. Using the time dependent Cox model, the adjusted dementia rate 
ratios (95% confidence interval) among current and former users were 0.93 (0.71-
1.21) and 0.99 (0.79-1.25). Use of IPTW resulted in similar findings with rate ratios 
(95% conservative confidence interval) of 1.24 (0.89-1.72) among current users 
and 0.94 (0.67-1.31) for former users as compared with the nonusers. 
CONCLUSIONS: This study found no difference in risk of dementia among the 
current and former users of statin as compared with the nonusers in an already 
at-risk HF population.  
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OBJECTIVES: The purpose of this study was to examine the rate of myocardial 
infarctions (MI) and associated event costs in patients prescribed clopidogrel and 
a concomitant PPI. METHODS: This was a retrospective study of administrative 
claims using the IMS Lifelink Database. Adult GERD patients concomitantly 
prescribed clopidogrel and PPI ≥ 30 days from July 1, 2005-December 31, 2009 
were identified. Patients were required to have continuous insurance coverage 
for ≥ 6 months prior to the concomitant therapy start date. Patients were 
followed until a MI (based upon emergency department or inpatient 
hospitalization diagnosis), medication discontinuation, loss of insurance 
coverage, or one year, whichever occurred first. RESULTS: A total of 64,370 
PPI+clopidogrel patients (40.3% female) were identified. Of these, 17,260 (26.8%) 
were prescribed esomeprazole, 7,237 (11.2%) received lansoprazole, 24,510 (38.1%) 
received omeprazole, 13,373 (20.8%) received pantoprazole, and 1,990 (3.1%) 
received rabeprazole. Rates of MI in these patients ranged from 3.1% (4.74 per 100 
person years) for rabeprazole to 6.3% (10.31 per 100 person years) for 
pantoprazole. Cox proportional hazards model controlling for gender, age, 
Charlson comorbidity index score, and cardiovascular comorbid conditions at 
baseline, showed the risk of MI was significantly lower for rabeprazole (adjusted 
hazard ratio [HR]=0.753; P=0.0315), lansoprazole (HR=0.870; P=0.0373), and 
esomeprazole (HR=0.893; P=0.0203) when compared to omeprazole, while higher 
for pantoprazole (HR=1.197; P=0.0001). The average MI hospitalization event cost 
for patients with an event was $31,806, and the average MI-related emergency 
department visit cost was $1,934. CONCLUSIONS: The rate of MI was different 
among PPIs when used in combination with clopidogrel. These differences in MI 
rates may have important clinical implications as well as a significant economic 
impact given the high cost of MI-related hospitalizations and emergency 
department visits. Further studies are needed to evaluate the differences 
between these cohorts.  
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OBJECTIVES: Discontinuation rates for vitamin K antagonists (VKAs) are high in 
patients with atrial fibrillation (AF). The aim of the current study was to assess 
the impact of VKA persistence compared to that of rivaroxaban, a new oral 
anticoagulant (NOAC) taken once daily and requiring no monitoring, on the 
incidence of ischemic strokes in patients with AF. METHODS: Data relating to 
persistence rates of warfarin and rivaroxaban over 18 months of patient follow-
up was derived from the literature. A model was developed synthesising these 
data with published ischaemic stroke rates and the effect of switching to an 
alternative treatment. The model assumed an annual risk of ischaemic stroke of 
1.65% and 5.00% for patients receiving warfarin or no treatment, respectively. To 
obtain the risk of stroke for patients receiving rivaroxaban, a relative risk of 0.94 
was applied to the warfarin risk giving an annual probability of 1.55%. 
Publications suggest that persistence after 180 days is 44% for warfarin and 78% 
for rivaroxaban. Sensitivity analyses on persistence rates of rivaroxaban were 
conducted to account for uncertainty. RESULTS: Patients starting treatment with 
a VKA stayed on treatment for an average of 226 days. In contrast, patients 
starting on rivaroxaban stayed on treatment for approximately 412 days. The 
total ischaemic stroke risk at 18 months was estimated to be 5.15% and 3.48–
4.07% for patients initiating therapy with warfarin or rivaroxaban, respectively. 
For a hypothetical cohort of 10,000 patients with AF the sensitivity analyses 
showed that the greater persistence with rivaroxaban would translate to 108–167 
strokes avoided. CONCLUSIONS: Our model indicates that starting patients on 
rivaroxaban may decrease the number of total ischaemic strokes relative to 
warfarin treatment. Moreover, this decrease may correspondingly reduce the 
burden of stroke-related costs borne by health care systems.  
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OBJECTIVES: To determine the pattern and predictors of use of acute 
pharmacological treatment (anti-platelet agents and beta-blockers) given in the 
emergency department (ED) to older adults with acute myocardial infarction 
(AMI). METHODS: Data from the National Hospital Ambulatory Medical Care 
Survey (NHAMCS) ED component from years 1992 to 2010 were used for the 
cross-sectional study. Patients were included if they had an admission diagnosis 
of AMI (ICD-9-CM code 410.xx) and were ≥55 years. Drug users were divided into 
4 groups: anti-platelet agents only, beta-blockers only, anti-platelet agents & 
beta-blockers, and non-users. Survey logistic regression was used to examine the 
trend in the use of drugs across the years and whether age predicted drug use. 
All the visits were weighted to obtain national estimates. All the analysis were 
carried out in SAS 9.3. RESULTS: A total of 1771 visit (weighted: 6.1 million visits) 
by patients were selected for this study. Almost 54% [95% CI: 51.7% to 57.1%] of 
our population are females with a mean age of 72 (SE=0.33) years. This 
population is 87% white [95% CI: 84.9% to 89.1%] and 94% non-Hispanic [95% CI: 
91.8% to 95.3%]. Both anti-platelet agents and beta-blockers showed to have a 
positive trend across the years (OR=1.09 [95% CI: 1.07 to 1.19] and OR=1.16 [95% 
CI: 1.13 to 1.19], respectively). Age was a significant predictor of anti-platelet 
agents use (OR=0.76 [95% CI: 0.62 to 0.93]), older adults (≥65) were less likely to 
receive an anti-platelet agent than younger adults; however, age was not 
considered to be a significant predictor of beta-blocker use. CONCLUSIONS: This 
study displayed a positive pattern across the years in the use of acute 
pharmacological treatment given for older AMI patients. It also suggested that 
older adults were less likely to be treated acutely with anti-platelet agents.  
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OBJECTIVES: Cardiovascular diseases (CVDs) are the leading cause of 
death/disability in Qatar. Nonetheless, there are no any Qatari data that 
describes the patterns of using drugs for the CVD. This study sought to assess 
changes in the ‘utilization’ and ‘expenditures’ of cardiovascular drugs over time. 
METHODS: The study is conducted from the Hamad Medical Corporation (HMC) 
setting, whereby utilization and expenditures data were obtained from HMC 
drug databases that are based on the 2007- 2011 period. Data were categorized by 
drug, drug concentration, drug class, year, and hospital. Descriptive statistics 
were used to illustrate distributions of variables, and cross-tabulation was used 
to provide comparison of frequency data. RESULTS: An increasing trend in 
utilization and expenditures was associated with the use of cardiovascular 
drugs. The rise in expenditure was more substantial as compared to utilization 
